qa:qa_dcx-login
Question & Answer
A: Diagnostic testing for C. difficile should be performed only in patients with clinically significant diarrhea (patients with 3 or more loose stools in ≤24 hours) who have risk factors for CDI such as recent exposure to antibiotics, older age, and/or duration of stay at a hospital or nursing facility.1 Acceptable samples should be unformed stool specimens that take the shape of the container.
A: Diagnostic testing for C. difficile should be performed only in patients with clinically significant diarrhea (patients with 3 or more loose stools in ≤24 hours) who have risk factors for CDI such as recent exposure to antibiotics, older age, and/or duration of stay at a hospital or nursing facility.1 Acceptable samples should be unformed stool specimens that take the shape of the
- Automate data transfer to ensure data quality
- Choose from LIS configuration options to enable
workflow flexibility - Improve resource efficiency with streamlined data management
GeneXpert Systems can interface with multiple LIS, middleware, EMR and POC data managers from vendor, Radiometer.
Check with your Cepheid Representative for a complete list of available LIS & middleware interfaces.
- Automate data transfer to ensure data quality
- Choose from LIS configuration options to enable
workflow flexibility - Improve resource efficiency with streamlined data management
GeneXpert Systems can interface with multiple LIS, middleware, EMR and POC data managers from vendor, Radiometer.
Check with your Cepheid Representative for a complete list of available LIS & middleware interfaces.
You can go there
A: Molecular tests/NAATs are designed to detect DNA from Clostridium difficile organisms capable of producing toxin (also referred to as toxigenic C. difficile) found in stool. PCR is one type of NAAT. The sensitivity of detection of toxigenic C. difficile organism by GeneXpert has been reported to be 94–99%2-4 and correlated well with a clinical diagnosis of C. difficile infection (CDI).2 Commercially available molecular assays are not designed to assess host response or to determine if the patient requires treatment, although they do provide valuable information to the physician when used in the context of other clinical features. In addition, 80–90% of samples tested for C. difficile are negative. Because they are very sensitive, molecular tests can be used to “rule out” C. difficile in the majority of patients more confidently than with immunologic methods. Thus, a rapid and sensitive molecular test can help to avoid unnecessary empiric therapy that is often administered to patients during the time clinicians are waiting for lab results (as described below).
A: Molecular tests/NAATs are designed to detect DNA from Clostridium difficile organisms capable of producing toxin (also referred to as toxigenic C. difficile) found in stool. PCR is one type of NAAT. The sensitivity of detection of toxigenic C. difficile organism by GeneXpert has been reported to be 94–99%2-4 and correlated well with a clinical diagnosis of C. difficile infection (CDI).2 Commercially available molecular assays are not designed to assess host response or to determine if the patient requires treatment, although they do provide valuable information to the physician when used in the context of other clinical features. In addition, 80–90% of samples tested for C. difficile are negative. Because they are very sensitive, molecular tests can be used to “rule out” C. difficile in the majority of patients more confidently than with immunologic methods. Thus, a rapid and sensitive molecular test can help to avoid unnecessary empiric therapy that is often administered to patients during the time clinicians are waiting for lab results (as described below).
A: Molecular tests/NAATs are designed to detect DNA from Clostridium difficile organisms capable of producing toxin (also referred to as toxigenic C. difficile) found in stool. PCR is one type of NAAT. The sensitivity of detection of toxigenic C. difficile organism by GeneXpert has been reported to be 94–99%2-4 and correlated well with a clinical diagnosis of C. difficile infection (CDI).2 Commercially available molecular assays are not designed to assess host response or to determine if the patient requires treatment, although they do provide valuable information to the physician when used in the context of other clinical features. In addition, 80–90% of samples tested for C. difficile are negative. Because they are very sensitive, molecular tests can be used to “rule out” C. difficile in the majority of patients more confidently than with immunologic methods. Thus, a rapid and sensitive molecular test can help to avoid unnecessary empiric therapy that is often administered to patients during the time clinicians are waiting for lab results (as described below).
A: Molecular tests/NAATs are designed to detect DNA from Clostridium difficile organisms capable of producing toxin (also referred to as toxigenic C. difficile) found in stool. PCR is one type of NAAT. The sensitivity of detection of toxigenic C. difficile organism by GeneXpert has been reported to be 94–99%2-4 and correlated well with a clinical diagnosis of C. difficile infection (CDI).2 Commercially available molecular assays are not designed to assess host response or to determine if the patient requires treatment, although they do provide valuable information to the physician when used in the context of other clinical features. In addition, 80–90% of samples tested for C. difficile are negative. Because they are very sensitive, molecular tests can be used to “rule out” C. difficile in the majority of patients more confidently than with immunologic methods. Thus, a rapid and sensitive molecular test can help to avoid unnecessary empiric therapy that is often administered to patients during the time clinicians are waiting for lab results (as described below).
A: Molecular tests/NAATs are designed to detect DNA from Clostridium difficile organisms capable of producing toxin (also referred to as toxigenic C. difficile) found in stool. PCR is one type of NAAT. The sensitivity of detection of toxigenic C. difficile organism by GeneXpert has been reported to be 94–99%2-4 and correlated well with a clinical diagnosis of C. difficile infection (CDI).2 Commercially available molecular assays are not designed to assess host response or to determine if the patient requires treatment, although they do provide valuable information to the physician when used in the context of other clinical features. In addition, 80–90% of samples tested for C. difficile are negative. Because they are very sensitive, molecular tests can be used to “rule out” C. difficile in the majority of patients more confidently than with immunologic methods. Thus, a rapid and sensitive molecular test can help to avoid unnecessary empiric therapy that is often administered to patients during the time clinicians are waiting for lab results (as described below).